UNSPSC 51385614: Aspirin calcium

This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C9H7O4.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WOD7W0DGZS, chemically known as 2-(acetyloxy)benzoic acid calcium salt, but more generally known as aspirin calcium, which bears US NIH Compound Identifier 6247. European Medicines Agency schedules aspirin calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435. Most nations, for tariff purposes, schedule aspirin calcium under HS 29182200.

Aspirin calcium bears US NLM identifiers UMLS ID C2006111 and NCI Concept Code C83539. SMILES: CC(=O)OC1CCCCC1C(=O)[O-].CC(=O)OC1CCCCC1C(=O)[O-].[CA+2].

UNSPSC 51385614 Aspirin calcium (Commodity) covers pharmaceutical products and over-the-counter medications that state and local governments procure for public health, emergency response, and employee wellness programs. Recent solicitations under this code show state and local buyers purchasing naloxone, generic pharmaceuticals, OTC products, and related therapeutic items through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Work solicited ranges from emergency-response drug procurement to comprehensive generic pharmaceutical supply agreements serving multiple jurisdictions through authorized wholesale distributors.

Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and awards effective July 1, 2026; the procurement emphasizes price competitiveness (75 percent of evaluation weight) and requires vendors to maintain $5 million commercial general liability insurance and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as a preliminary market-intelligence solicitation to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Recent activity spans Florida, Minnesota (serving multiple states including Oregon), and Texas, with geographic reach extending through cooperative purchasing mechanisms.